Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.
Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (P trend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.
Infections and Immunoepidemiology Branch .
Thomas R
TR
O'Brien
Infections and Immunoepidemiology Branch .
Krystle A
KA
Lang Kuhs
Biostatistics Branch, Division of Cancer Epidemiology and Genetics , National Cancer Institute , Bethesda, Maryland.
Ruth M
RM
Pfeiffer
IFNL4; clinical trial; cost-effectiveness; direct-acting antiviral agents; gender; hepatitis C virus